These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 25444987)
1. Prognostic impact of synchronous second primary malignancies on the overall survival of patients with metastatic prostate cancer. Koo KC; Yoo H; Kim KH; Park SU; Han KS; Rha KH; Hong SJ; Yang SC; Chung BH J Urol; 2015 Apr; 193(4):1239-44. PubMed ID: 25444987 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer. Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961 [TBL] [Abstract][Full Text] [Related]
3. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR Cancer; 2007 Mar; 109(6):1192-202. PubMed ID: 17311344 [TBL] [Abstract][Full Text] [Related]
4. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. Halabi S; Vogelzang NJ; Ou SS; Small EJ J Urol; 2007 Feb; 177(2):531-4. PubMed ID: 17222627 [TBL] [Abstract][Full Text] [Related]
5. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis]. Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221 [TBL] [Abstract][Full Text] [Related]
6. Synchronous and metachronous malignancies: analysis of the Minneapolis Veterans Affairs (VA) tumor registry. Powell S; Tarchand G; Rector T; Klein M Cancer Causes Control; 2013 Aug; 24(8):1565-73. PubMed ID: 23737025 [TBL] [Abstract][Full Text] [Related]
7. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED; J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721 [TBL] [Abstract][Full Text] [Related]
8. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy. Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985 [TBL] [Abstract][Full Text] [Related]
9. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Grytli HH; Fagerland MW; Fosså SD; Taskén KA Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721 [TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441 [TBL] [Abstract][Full Text] [Related]
11. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760 [TBL] [Abstract][Full Text] [Related]
13. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. Graff JN; Mori M; Li H; Garzotto M; Penson D; Potosky AL; Beer TM J Urol; 2007 Apr; 177(4):1307-12. PubMed ID: 17382720 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204 [TBL] [Abstract][Full Text] [Related]
15. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687 [TBL] [Abstract][Full Text] [Related]
16. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. Tollefson MK; Leibovich BC; Slezak JM; Zincke H; Blute ML J Urol; 2006 Feb; 175(2):547-51. PubMed ID: 16406993 [TBL] [Abstract][Full Text] [Related]
17. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer. Tendulkar RD; Hunter GK; Reddy CA; Stephans KL; Ciezki JP; Abdel-Wahab M; Stephenson AJ; Klein EA; Mahadevan A; Kupelian PA Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):94-9. PubMed ID: 23920389 [TBL] [Abstract][Full Text] [Related]
18. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. Goyal J; Pond GR; Galsky MD; Hendricks R; Small A; Tsao CK; Sonpavde G Urol Oncol; 2014 Jan; 32(1):36.e27-34. PubMed ID: 23685020 [TBL] [Abstract][Full Text] [Related]
19. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342 [TBL] [Abstract][Full Text] [Related]